Please ensure Javascript is enabled for purposes of website accessibility

Here's the Biggest Problem Ocugen Faces Right Now

By Adria Cimino - Updated Mar 7, 2021 at 9:56AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This point will determine just how much Ocugen can profit from its potential coronavirus vaccine.

Ocugen (OCGN -7.79%) is a latecomer to the coronavirus vaccine race. It recently gained rights to co-commercialize Bharat Biotech's vaccine candidate in the U.S. In this Motley Fool Live video, recorded on Feb. 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss Ocugen's partnership with the India-based company -- and whether the companies can potentially carve out a share of the U.S. market.

Corinne Cardina: A lot of the companies we've talked about, we've been talking about them for quite a while, for some of them, a little under a year. But just this month, a new name has popped up on the vaccine horizon and that is Ocugen. This is a company that is developing gene therapy for eye diseases. But it said it's bringing a vaccine candidate to the FDA. It's doing a deal with an Indian company called Bharat Biotech, and it's going to commercialize Bharat's vaccine in the U.S. What should investors know about this latecomer to the vaccine race? Do you think it could carve out a share of the U.S. market?

Adria Cimino: Well, I think it's going to be difficult. I think that Covaxin is already authorized in India, we don't have phase 3 data yet on it. But supposedly it produces a broad immune response beyond the spike and that means that it could handle strains. So that sounds good and if that turns out to be the fact in the phase 3 trials, great. My one concern though is Ocugen has this deal for co-commercialization in the U.S. -- and that's where we now have enough vaccine ordered for this year. I think it's going to be really difficult. I think there's going to be a lot of competition in the U.S. right away. Unless the vaccine is a whole lot better than rivals, it's really going to face some difficult competition. I would say for now remain cautious on this stock and just keep watching and see. It might be some long-term opportunity, but right now remain cautious.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$2.25 (-7.79%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.